¼¼°èÀÇ »ó±âµµ °¨¿° Ä¡·á ½ÃÀå
Upper Respiratory Tract Infection Treatment
»óǰÄÚµå : 1793922
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 372 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ó±âµµ °¨¿° Ä¡·á ½ÃÀåÀº 2030³â±îÁö 149¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 128¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ »ó±âµµ °¨¿° Ä¡·á ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 2.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 149¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ç×»ýÁ¦´Â CAGR 3.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 82¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à¡¤ºñ°­ ÃæÇ÷ Á¦°Å¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 1.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 35¾ï ´Þ·¯, Áß±¹Àº CAGR 5.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ó±âµµ °¨¿° Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 35¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 29¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 5.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 0.9%¿Í 2.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »ó±âµµ °¨¿° Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ó±âµµ °¨¿° Ä¡·á°¡ °øÁߺ¸°ÇÀÇ ¿ì¼±¼øÀ§°¡ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°¨±â, Àεο°, ºÎºñµ¿¿°, Èĵο°, Æíµµ¼±¿° µîÀÇ Áúº´À» Æ÷ÇÔÇÑ »ó±âµµ °¨¿°(UTI)Àº Àü ¼¼°è¿¡¼­ °¡Àå ±¤¹üÀ§ÇÑ °Ç°­ ¹®Á¦ Áß ÇϳªÀÌ¸ç ¸ðµç ¿¬·É´ëÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°Àº ÁÖ·Î ¹ÙÀÌ·¯½º¼º °¨¿°ÀÌ ÁÖ¸¦ ÀÌ·çÁö¸¸, ¼¼±Õ¼º °¨¿°µµ »ó´ç ºÎºÐÀ» Â÷ÁöÇϸç, ƯÈ÷ ÁßÁõÈ­µÇ°Å³ª Àå±âÈ­µÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¿ä·Î°á¼®Àº ÀÚ¿¬ Ä¡À¯µÇ´Â °æ¿ì°¡ ¸¹À½¿¡µµ ºÒ±¸ÇÏ°í ³ôÀº ÀÌȯÀ², °æÁ¦Àû ºÎ´ã, °ü¸® ¹ÌÈí½Ã ÇÕº´Áõ ¹ß»ý °¡´É¼ºÀ¸·Î ÀÎÇØ °øÁߺ¸°ÇÇÐÀûÀ¸·Î Å« ¹®Á¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ Çб³, Á÷Àå, ´ëÁß±³Åë°ú °°ÀÌ Àα¸ ¹ÐÁýµµ°¡ ³ôÀº ȯ°æ¿¡¼­´Â °¨¿°ÀÌ ¿ëÀÌÇϹǷΠÀϳ⠳»³» Ç×»ó Á¸ÀçÇϸç, Ãß¿î °èÀý¿¡ °èÀýÀûÀ¸·Î ÃÖ°íÁ¶¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. Ä¡·áÀÇ °üÁ¡¿¡¼­ º¼ ¶§, ¿ä·Î°á¼®Àº Àü ¼¼°è¿¡¼­ ¿Ü·¡ Áø·á¿Í ó¹æÀü ¾øÀÌ ±¸ÀÔÇÒ ¼ö ÀÖ´Â ¾àǰÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ¶ÇÇÑ ¿ä·Î°á¼®Àº ºÒÇÊ¿äÇÑ Ç×»ýÁ¦ ó¹æÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, Ç×±ÕÁ¦ ³»¼º ¹®Á¦¸¦ ¾ß±âÇÏ´Â ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù. °øÁß º¸°Ç ´ç±¹°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â È¿°úÀûÀÎ Áõ»ó ¿ÏÈ­¿Í ¾à¹° Ä¡·áÀÇ Çö¸íÇÑ »ç¿ëÀÇ ±ÕÇüÀ» ¸ÂÃß´Â µ¥ Á¡Á¡ ´õ ¸¹Àº ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ºÒÆíÇÔÀ» ¿ÏÈ­Çϰí, °¨¿° ±â°£À» ´ÜÃàÇϰí, °ú´Ù Åõ¾àÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Â ±Ù°Å¿¡ ±â¹ÝÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¿ä·Î°á¼® Ä¡·á´Â ¿©ÀüÈ÷ ÀÇ·á ½Ã½ºÅÛ, ÀǾàǰ °³¹ß ±â¾÷ ¹× ¼¼°è º¸°Ç±â±¸ÀÇ Áß¿äÇÑ °ü½É»ç°¡ µÇ°í ÀÖ½À´Ï´Ù.

ÁøÈ­ÇÏ´Â Ä¡·á¹ý°ú ¾à¹° Çõ½ÅÀº ¿ä·Î°á¼® °ü¸®¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

Çõ½ÅÀûÀÎ ¾à¹°ÀÇ µµÀÔ, ¾à¹°Àü´ÞÀÇ °³¼±, Áõ°Å¿¡ ±â¹ÝÇÑ Ä¡·á Àü·«ÀÇ Á߿伺À¸·Î ÀÎÇØ »ó±âµµ °¨¿° Ä¡·áÀÇ »óȲÀº ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÃæÇ÷Á¦°ÅÁ¦, ÇØ¿­Á¦, Ç×È÷½ºÅ¸¹ÎÁ¦, ÁøÇØÁ¦¸¦ ÅëÇÑ Áõ»ó ¿ÏÈ­´Â ¿©ÀüÈ÷ ¿ä·Î°á¼® °ü¸®ÀÇ ±âº»ÀÌÁö¸¸, ȯÀÚÀÇ ÆíÀǼº°ú ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ ¿©·¯ Áõ»óÀ» µ¿½Ã¿¡ Ä¡·áÇÏ´Â º´¿ë¿ä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼­¹æÇü Á¤Á¦, Á¡ºñÁ¦, ±¹¼Ò ÀÛ¿ëÇÏ´Â Æ®·ÎÄ¡Á¦ µî ÷´Ü Á¦Á¦ÀÇ °³¹ß·Î Áõ»ó Á¶ÀýÀÇ ¼Óµµ¿Í È¿°ú°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¼¼±Õ °¨¿°ÀÇ °æ¿ì ³»¼º±ÕÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ±¤¹üÀ§ Ç×»ýÁ¦º¸´Ù Çù´ë¿ª Ç×»ýÁ¦°¡ ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ƯÁ¤ ¹ÙÀÌ·¯½º ±ÕÁÖ¸¦ º¸´Ù È¿°úÀûÀ¸·Î Ä¡·áÇϱâ À§ÇØ »õ·Î¿î Ç×¹ÙÀÌ·¯½ºÁ¦, ƯÈ÷ ¸é¿ª·ÂÀÌ ¾àÇÑ Áý´ÜÀ̳ª ¹ÙÀÌ·¯½º¼º Àεο°, ½ÉÇÑ °¨±â Áõ»óÀÇ °æ¿ì »õ·Î¿î Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í ¾à¹°À¯ÀüüÇÐÀÇ µîÀåÀ¸·Î °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀϰú ¸é¿ª ¹ÝÀÀ¿¡ ¸ÂÃá Ä¡·áÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ½Ä¿°¼ö °ü°³, Çãºê ÃßÃâ¹°, ¸é¿ª·Â °­È­ ¿µ¾çÁ¦ µî ºñ¾à¹°ÇÐÀû Ä¡·á¹ýÀÌ º¸¿ÏÀûÀÎ Ä¡·á¹ýÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¿ä·Î°á¼® Ä¡·á¿¡ ´ëÇÑ º¸´Ù ÃÑüÀûÀ̰í ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½Ä¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Ä¡·á Çõ½ÅÀº ºü¸¥ ȸº¹»Ó¸¸ ¾Æ´Ï¶ó ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí Àå±âÀûÀΠȣÈí±â °Ç°­À» ÁõÁøÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

Àα¸Åë°è, °èÀý¼º, ÀÇ·á ÀÎÇÁ¶ó°¡ Ä¡·á ¼ö¿ä¿¡ ¹ÌÄ¡´Â ¿ªÇÒÀº?

»ó±âµµ °¨¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â Àα¸ Åë°è, °èÀýÀû ÆÐÅÏ, Àû½Ã¿¡ Ä¡·á¸¦ Á¦°øÇÏ´Â ÀÇ·á ½Ã½ºÅÛÀÇ ´É·Â°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¾î¸°ÀÌ¿Í ³ëÀÎÀº ¸é¿ª ü°è°¡ »ó´ëÀûÀ¸·Î ¾àÇϰųª ¹ß´ÞÇÏÁö ¾Ê¾Æ °¡Àå Ãë¾àÇÑ Áý´ÜÀ¸·Î ¹ßº´·üÀÌ ³ô°í ÇÕº´ÁõÀ» À¯¹ßÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ƯÈ÷ ¼Ò¾Æ ¿ä·Î°á¼®ÀÇ °æ¿ì, Çб³ °á¼®°ú ºÒÆíÇÔÀ» ÁÙÀ̱â À§ÇØ ºÎ¸ðµéÀÌ ½Å¼ÓÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã±â À§ÇØ ¸¹Àº ÀÓ»ó Áø·á¿Í Åõ¾àÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î ÇÕº´ÁõÀÌ ÀÖ´Â ³ëÀÎÀº 2Â÷ °¨¿° ¹× ÀÔ¿ø À§ÇèÀÌ ³ô±â ¶§¹®¿¡ º¸´Ù ½ÅÁßÇÑ Ä¡·á Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. °èÀý¼ºµµ Å« ¿äÀÎ Áß Çϳª·Î, ½Ç³» È¥Àâ°ú °ø±â ¼øÈ¯ ÀúÇÏ·Î ÀÎÇØ ¹ÙÀÌ·¯½º°¡ ±Þ¼ÓÈ÷ È®»êµÇ´Â Ãß¿î ½Ã±â³ª ¿ì±â¿¡ °¨¿°ÀÚ°¡ ±ÞÁõÇÕ´Ï´Ù. ±âÈÄ, Àα¸¹Ðµµ, ¿À¿°µµ µî Áö¿ªÀû Â÷À̵µ °¨¿°·ü°ú Ä¡·á¹ý¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó´Â ½Å¼ÓÇÑ Áø´Ü, ÀûÀýÇÑ ¾àǰÀÇ È®º¸, È¿°úÀûÀÎ °øÁߺ¸°Ç ¸Þ½ÃÁö Àü´Þ µî Àß °®Ãß¾îÁø ½Ã½ºÅÛÀ» ÅëÇØ Ä¡·áÀÇ Á¢±Ù¼º°ú Áú¿¡ °áÁ¤ÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. À̿ʹ ´ëÁ¶ÀûÀ¸·Î, ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â Áö¿ª¿¡¼­´Â Áø´Ü°ú Ä¡·á°¡ ´Ê¾îÁö°í, Áúº´ÀÌ Àå±âÈ­µÇ°Å³ª ÀÏ¹Ý ÀǾàǰ¿¡ °úµµÇÏ°Ô ÀÇÁ¸ÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÇ ÅëÇÕÀº ƯÈ÷ µµ½Ã Áö¿ª¿¡¼­ ½ÇÁ¦ Áø·á¼Ò¸¦ ¹æ¹®ÇÏÁö ¾Ê°íµµ º¸´Ù ½Å¼ÓÇÑ Áø·á, µðÁöÅРó¹æ, °æ°ú °üÂûÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ¿ä·Î°á¼® °ü¸® ¹æ¹ý¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸Åë°èÇÐÀû, ±¸Á¶Àû ¿äÀÎÀÌ °¢ Áö¿ªÀÇ »ó±âµµ °¨¿° Ä¡·áÀÇ ±Ô¸ð, ½Ã±Þ¼º, ÇüŸ¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

»ó±âµµ °¨¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

»ó±âµµ °¨¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¿ªÇÐ µ¿Çâ, ¼ÒºñÀÚ Çൿ, ÇコÄɾî Çõ½ÅÀÇ Á¶ÇÕÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. °¡Àå Å« ¿øµ¿·Â Áß Çϳª´Â Àü ¼¼°è¿¡¼­ ¿ä·Î°á¼®ÀÇ À¯º´·üÀÌ Áö¼ÓÀûÀ¸·Î ³ô¾Æ 󹿾à°ú ÀϹÝÀǾàǰ ¸ðµÎ¿¡ ´ëÇÑ ¾ÈÁ¤ÀûÀ̰í Áö¼ÓÀûÀÎ ¼ö¿ä°¡ È®º¸µÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°¼º ÁúȯÀÌ ¸¸¿¬ÇÏ´Ù´Â °ÍÀº Ä¡·á È¿°ú¿Í Á¢±Ù¼ºÀÌ Á¶±ÝÀÌ¶óµµ °³¼±µÈ´Ù¸é Å« ½ÃÀå ÀÌÀÍÀ¸·Î À̾îÁú ¼ö ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä ¿äÀÎÀº ºü¸¥ Áõ»ó ¿ÏÈ­ ¹× ¿©·¯ Áõ»ó¿¡ ´ëÀÀÇÏ´Â Á¦Çü¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ º¸´Ù Áøº¸µÈ Á¦Çü°ú Àü´Þ ÇüŰ¡ °³¹ßµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼Ò¸Å ¾à±¹ üÀÎ, E-Commerce ÀǾàǰ Ç÷§Æû, ¿ø°ÝÀÇ·á ¼­ºñ½ºÀÇ È®´ëµµ ¼ÒºñÀÚ°¡ º´¿øÀ̳ª Áø·á¼Ò¸¦ ¹æ¹®ÇÏÁö ¾Ê°íµµ ½±°Ô Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. Ç×»ýÁ¦ ¿À³²¿ëÀÇ À§Ç輺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎ º¸´Ù Ã¥ÀÓ°¨ ÀÖ´Â Ä¡·á¹ýÀ» äÅÃÇϰí, ¾àÃÊ ¹× µ¿Á¾¿ä¹ý°ú °°Àº ´ëü¿ä¹ý ¹× ÁöÁö¿ä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï ±¹°¡¿¡¼­´Â °Ç°­ º¸ÇèÀÌ º¸ÆíÈ­µÇ¸é¼­ ºê·£µå ÀǾàǰ¿¡ ´ëÇÑ Á¢±Ù¼º°ú Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ¼Ò¾Æ Àü¿ë Á¦Á¦, »õ·Î¿î Ç×¹ÙÀÌ·¯½ºÁ¦, ´õ ³ªÀº ³»¾à¼º µî¿¡ ÁßÁ¡À» µÎ°í ¿ä·Î°á¼® Ä¡·áÁ¦ Æ÷Æ®Æú¸®¿À¸¦ Â÷º°È­Çϱâ À§ÇØ Å¸°ÙÆÃµÈ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. È£Èí±â À§»ý°ú Á¶±â Áõ»ó °ü¸®¸¦ À§ÇÑ °øÁߺ¸°Ç Ä·ÆäÀÎÀº Ä¡·á¿¡ ´ëÇÑ Àû±ØÀûÀÎ Á¢±Ù¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÈûÀÇ °áÁýÀ¸·Î »ó±âµµ °¨¿° Ä¡·á ½ÃÀåÀº ¸ðµç ¿¬·ÉÃþ°ú ÀÇ·á ½Ã½ºÅÛÀ» ¾Æ¿ì¸£´Â °ß°íÇϰí ÁøÈ­ÇÑ ½ÃÀåÀ¸·Î, ¾ÕÀ¸·Îµµ Áö¼ÓÀûÀÎ Çõ½Å°ú È®ÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

À¯Çü(Ç×»ýÁ¦, ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿° ÁøÅëÁ¦, ±âŸ Ä¡·áÁ¦); À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹); È¿´É¡¤È¿°ú(°¨±â, ºÎºñ°­¿°, Àεο°, Èĵο°)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Upper Respiratory Tract Infection Treatment Market to Reach US$14.9 Billion by 2030

The global market for Upper Respiratory Tract Infection Treatment estimated at US$12.8 Billion in the year 2024, is expected to reach US$14.9 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the NSAIDs & Nasal Decongestants segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 5.2% CAGR

The Upper Respiratory Tract Infection Treatment market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Upper Respiratory Tract Infection Treatment Market - Key Trends & Drivers Summarized

Why Does the Treatment of Upper Respiratory Tract Infections Remain a Public Health Priority?

Upper respiratory tract infections (URTIs), which include ailments such as the common cold, pharyngitis, sinusitis, laryngitis, and tonsillitis, continue to be among the most widespread health issues globally, affecting individuals across all age groups. These infections are primarily viral in origin, though bacterial agents also contribute to a significant portion of cases, particularly in more severe or prolonged episodes. Despite being self-limiting in many instances, URTIs represent a major public health concern due to their high incidence rate, economic burden, and potential to cause complications if inadequately managed. The ease of transmission, especially in densely populated settings like schools, workplaces, and public transportation, ensures their constant presence throughout the year, with seasonal peaks in colder months. From a treatment perspective, URTIs account for a large volume of outpatient visits and over-the-counter medication purchases globally. Additionally, they are one of the leading causes of unnecessary antibiotic prescriptions, contributing to the growing challenge of antimicrobial resistance. Public health authorities and healthcare providers are increasingly focused on balancing effective symptom relief with judicious use of pharmacological therapies. This has led to a surge in demand for targeted, evidence-based treatment options that alleviate discomfort, reduce infection duration, and minimize the risk of overmedication. As a result, treatment of URTIs remains a critical area of focus for healthcare systems, pharmaceutical developers, and global health organizations.

How Are Evolving Treatment Modalities and Drug Innovations Reshaping URTI Management?

The landscape of upper respiratory tract infection treatment is evolving with the introduction of innovative drugs, improved delivery mechanisms, and a greater emphasis on evidence-based therapeutic strategies. While symptomatic relief through decongestants, antipyretics, antihistamines, and cough suppressants remains the cornerstone of URTI management, there is increasing interest in combination therapies that address multiple symptoms simultaneously to enhance patient comfort and compliance. The development of advanced formulations, such as extended-release tablets, nasal sprays, and lozenges with localized action, is improving the speed and effectiveness of symptom control. In cases involving bacterial infections, narrow-spectrum antibiotics are being promoted over broad-spectrum alternatives to reduce the risk of resistance. At the same time, novel antiviral agents are being explored to treat specific viral strains more effectively, particularly in immunocompromised populations and in cases of viral pharyngitis or severe cold symptoms. The rise of personalized medicine and pharmacogenomics is also opening the door to treatments tailored to individual genetic profiles and immune responses. In parallel, non-pharmacological options such as saline irrigation, herbal extracts, and immune-boosting nutraceuticals are gaining popularity as complementary treatments. These trends are contributing to a more holistic and patient-centered approach to URTI care, where therapeutic innovation focuses not just on rapid recovery but also on minimizing side effects and promoting long-term respiratory health.

What Role Do Demographics, Seasonality, and Healthcare Infrastructure Play in Treatment Demand?

The demand for upper respiratory tract infection treatment is closely linked to demographic profiles, seasonal patterns, and the capacity of healthcare systems to deliver timely care. Children and the elderly represent the most vulnerable groups due to their comparatively weaker or less-developed immune systems, leading to higher incidence rates and a greater likelihood of complications. Pediatric URTI cases, in particular, drive significant volumes of clinical consultations and medication use, as parents seek fast and effective remedies to reduce school absenteeism and discomfort. Similarly, elderly populations with comorbid conditions are often at greater risk of secondary infections or hospitalization, requiring more careful treatment strategies. Seasonality is another major factor, with sharp increases in cases during colder months or rainy seasons when viruses spread more rapidly due to indoor crowding and reduced air circulation. Geographic differences in climate, population density, and pollution levels also influence infection rates and treatment approaches. Healthcare infrastructure plays a decisive role in the accessibility and quality of treatment, with well-equipped systems providing rapid diagnostics, access to appropriate medications, and effective public health messaging. In contrast, underserved regions may face delays in diagnosis and treatment, leading to prolonged illness or overreliance on over-the-counter solutions. The integration of telemedicine and digital health platforms is also influencing how URTIs are managed, particularly in urban centers, by enabling faster consultations, digital prescriptions, and follow-ups without the need for physical clinic visits. These demographic and structural factors collectively shape the scale, urgency, and mode of upper respiratory infection treatment across different regions.

What Are the Key Factors Driving Growth in the Upper Respiratory Tract Infection Treatment Market?

The growth in the upper respiratory tract infection treatment market is driven by a combination of epidemiological trends, consumer behavior, and healthcare innovation. One of the foremost drivers is the consistently high global incidence of URTIs, which ensures a stable and recurring demand for both prescription and over-the-counter therapies. The widespread nature of these infections means that even modest improvements in treatment effectiveness or accessibility can translate into significant market gains. Another key factor is the increasing consumer preference for rapid relief and multi-symptom formulations, which has led to the development of more advanced combination drugs and delivery formats. The expansion of retail pharmacy chains, e-commerce drug platforms, and telehealth services is also making it easier for consumers to access treatment without visiting a hospital or clinic. Rising awareness about the risks of antibiotic misuse is encouraging both patients and providers to adopt more responsible treatment practices, which is fueling interest in alternative and supportive therapies, including herbal and homeopathic options. Additionally, the growth of health insurance coverage in emerging economies is improving affordability and access to branded medications. Pharmaceutical companies are investing in targeted R&D to differentiate their URTI portfolios, focusing on pediatric-specific formulations, new antivirals, and better drug tolerability. Public health campaigns aimed at respiratory hygiene and early symptom management are further contributing to a proactive approach to care. These converging forces are creating a robust and evolving market for upper respiratory tract infection treatment that spans all age groups and healthcare systems, ensuring ongoing innovation and expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Upper Respiratory Tract Infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Antibiotics, NSAIDs & Nasal Decongestants, Other Treatments); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Indication (Common Cold, Sinusitis, Pharyngitis, Laryngitis)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â